NASDAQ:LBPH Longboard Pharmaceuticals (LBPH) Stock Price, News & Analysis $59.72 +0.02 (+0.03%) (As of 10/31/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Longboard Pharmaceuticals Stock (NASDAQ:LBPH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get LBPH alerts:Sign Up Key Stats Today's Range$59.65▼$59.7550-Day Range$27.58▼$59.7052-Week Range$3.60▼$59.79Volume707,869 shsAverage Volume1.14 million shsMarket Capitalization$2.32 billionP/E RatioN/ADividend YieldN/APrice Target$59.56Consensus RatingHold Company OverviewLongboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.Read More… The real reason Elon is fully endorsing Trump (Ad)Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. Watch this new documentary and you’ll discover what Elon knows, Longboard Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks33rd Percentile Overall ScoreLBPH MarketRank™: Longboard Pharmaceuticals scored higher than 33% of companies evaluated by MarketBeat, and ranked 830th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.2 / 5Analyst RatingHold Consensus RatingLongboard Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on 4 buy ratings, 5 hold ratings, and no sell ratings.Amount of Analyst CoverageLongboard Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Longboard Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Longboard Pharmaceuticals are expected to decrease in the coming year, from ($2.19) to ($2.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Longboard Pharmaceuticals is -27.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Longboard Pharmaceuticals is -27.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLongboard Pharmaceuticals has a P/B Ratio of 35.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Longboard Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted15.34% of the float of Longboard Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverLongboard Pharmaceuticals has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Longboard Pharmaceuticals has recently decreased by 3.90%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLongboard Pharmaceuticals does not currently pay a dividend.Dividend GrowthLongboard Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted15.34% of the float of Longboard Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverLongboard Pharmaceuticals has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Longboard Pharmaceuticals has recently decreased by 3.90%, indicating that investor sentiment is improving. News and Social Media2.8 / 5News Sentiment1.08 News SentimentLongboard Pharmaceuticals has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Longboard Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 8 people have searched for LBPH on MarketBeat in the last 30 days. This is a decrease of -27% compared to the previous 30 days.MarketBeat Follows7 people have added Longboard Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Longboard Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,090,010.00 in company stock.Percentage Held by InsidersOnly 4.64% of the stock of Longboard Pharmaceuticals is held by insiders.Percentage Held by Institutions63.28% of the stock of Longboard Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Longboard Pharmaceuticals' insider trading history. Receive LBPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Longboard Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address LBPH Stock News HeadlinesRandall Kaye Sells 16,667 Shares of Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) StockOctober 17, 2024 | insidertrades.comLONGBOARD PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Longboard Pharmaceuticals, Inc. - LBPHOctober 31 at 12:03 PM | businesswire.comEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.October 31, 2024 | Paradigm Press (Ad)SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LBPH and ARC on Behalf of ShareholdersOctober 17, 2024 | globenewswire.comHC Wainwright & Co. Downgrades Longboard Pharmaceuticals (LBPH)October 17, 2024 | msn.comStrong Valuation and Strategic Acquisition Drive Buy Rating for Longboard PharmaceuticalsOctober 16, 2024 | markets.businessinsider.comTruist Securities Downgrades Longboard Pharmaceuticals (LBPH)October 16, 2024 | msn.comSTOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Longboard Pharmaceuticals, Inc. – LBPHOctober 16, 2024 | globenewswire.comSee More Headlines LBPH Stock Analysis - Frequently Asked Questions How have LBPH shares performed this year? Longboard Pharmaceuticals' stock was trading at $6.03 at the beginning of 2024. Since then, LBPH shares have increased by 890.4% and is now trading at $59.72. View the best growth stocks for 2024 here. How were Longboard Pharmaceuticals' earnings last quarter? Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) announced its earnings results on Thursday, August, 1st. The company reported ($0.56) EPS for the quarter, missing analysts' consensus estimates of ($0.46) by $0.10. When did Longboard Pharmaceuticals IPO? Longboard Pharmaceuticals (LBPH) raised $75 million in an initial public offering on Friday, March 12th 2021. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Evercore ISI, Guggenheim Securities and Cantor served as the underwriters for the IPO. Who are Longboard Pharmaceuticals' major shareholders? Longboard Pharmaceuticals' top institutional investors include Emerald Advisers LLC (1.76%), Emerald Mutual Fund Advisers Trust (1.08%) and SG Americas Securities LLC (0.03%). Insiders that own company stock include Randall Kaye and Arena Pharmaceuticals Inc. View institutional ownership trends. How do I buy shares of Longboard Pharmaceuticals? Shares of LBPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Longboard Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Longboard Pharmaceuticals investors own include JPMorgan Chase & Co. (JPM), Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Visa (V) and Home Depot (HD). Company Calendar Last Earnings8/01/2024Today10/31/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LBPH CUSIPN/A CIK1832168 Webwww.longboardpharma.com Phone619-592-9775FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$59.56 High Stock Price Target$90.00 Low Stock Price Target$32.00 Potential Upside/Downside-0.3%Consensus RatingHold Rating Score (0-4)2.44 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-54,420,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-36.93% Return on Assets-34.52% Debt Debt-to-Equity RatioN/A Current Ratio20.95 Quick Ratio20.95 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.67 per share Price / Book35.76Miscellaneous Outstanding Shares38,900,000Free Float37,095,000Market Cap$2.32 billion OptionableOptionable Beta1.22 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report This page (NASDAQ:LBPH) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Longboard Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Longboard Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.